Cargando…

ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy

Detalles Bibliográficos
Autor principal:	Baek, Moo-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Coloproctology 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496455/ https://www.ncbi.nlm.nih.gov/pubmed/26161372 http://dx.doi.org/10.3393/ac.2015.31.3.81

Ejemplares similares

ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Zaanan, Aziz, et al.
Publicado: (2014)

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
por: Li, P, et al.
Publicado: (2013)

Timing of Adjuvant Chemotherapy in Colorectal Cancer Patients
por: Baek, Moo-Jun
Publicado: (2013)

Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy
por: Eren, Tulay, et al.
Publicado: (2020)

Correction: Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy
por: Eren, Tulay, et al.
Publicado: (2020)

Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy
por: Li, Sheng, et al.
Publicado: (2014)

The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
por: LIU, YONG-PING, et al.
Publicado: (2013)

Survivin may be a Key Target for Oxaliplatin
por: Baek, Moo Jun
Publicado: (2010)

Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy
por: Kumamoto, Kensuke, et al.
Publicado: (2019)

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
por: Sun, Jong-Mu, et al.
Publicado: (2012)

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
por: Ishibashi, Keiichiro, et al.
Publicado: (2021)

A Case of Liver Fibrosis with Splenomegaly after Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer
por: Kang, Gu Hyum, et al.
Publicado: (2013)

Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy
por: Chen, Jianfang, et al.
Publicado: (2016)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Adjuvant colon cancer chemotherapy: Is there an Indian standard of care?
por: Joshi, Rohit
Publicado: (2013)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis
por: Ma, Shou-Cheng, et al.
Publicado: (2015)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy
por: Shibasaki, Yuta, et al.
Publicado: (2023)

Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada
por: Attard, C.L., et al.
Publicado: (2010)

Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil
por: Han, Jae Joon, et al.
Publicado: (2014)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer
por: Huang, Ming-Yii, et al.
Publicado: (2023)

Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy
por: Leng, Xue-Feng, et al.
Publicado: (2012)

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
por: Lesterhuis, W J, et al.
Publicado: (2010)

Laparoscopic Right Hemicolectomy for Colon Cancer: Technically Feasible and Safe to Perform in Terms of Oncologic Outcomes
por: Baek, Moo Jun
Publicado: (2012)

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?
por: Roda, Desamparados, et al.
Publicado: (2018)

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX
por: Stroes, Charlotte I., et al.
Publicado: (2021)

ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy
por: Xian-jun, Feng, et al.
Publicado: (2014)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Adjuvant oxaliplatin-based chemotherapy effect after treatment of colorectal hepatic metastasis
por: Kang, Mee-Young, et al.
Publicado: (2021)

Oxaliplatin-Based Adjuvant Chemotherapy without Radiotherapy Can Improve the Survival of Locally-Advanced Rectal Cancer
por: Li, Jun, et al.
Publicado: (2014)

Adjuvant chemotherapy for colorectal cancer
por: Maughan, T S
Publicado: (2001)

Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis
por: Huang, Wen-Kuan, et al.
Publicado: (2021)

Oxaliplatin related lncRNAs prognostic models predict the prognosis of patients given oxaliplatin-based chemotherapy
por: Zhou, Qing-nan, et al.
Publicado: (2023)

ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis
por: Gay‐Bellile, Mathilde, et al.
Publicado: (2016)

Right- and left-sided stage III colon cancers present different prognostic outcomes of oxaliplatin-based adjuvant chemotherapy after curative resection
por: Peng, Jianhong, et al.
Publicado: (2018)

Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
por: Wang, Guoxiu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7sqk3qnpn0nv7497dfcmkrmu3j